Johnson & Johnson subsidiary Cordis Corp has reported the results of apilot study which has found an unprecedentedly-low rate of restenosis in patients undergoing revascularization procedures accompanied by intracoronary stenting.
The latest results from a pilot study involving 45 patients who received Cordis' Velocity stent, coated with American Home Products' immunosuppressant drug Rapamune (sirolimus), has revealed that none of the first 15 patients, enrolled in Brazil, have any signs of restenosis after 12 months of follow-up. A similar situation was seen in a further 15 Dutch patients at the six-month timepoint, according to Patrick Serruys of Erasmus University in Rotterdam, the Netherlands, one of the principal investigators in the study.
Eduardo Sousa, from the Dante Pazzanese Institute of Cardiology in Sao Paulo, Brazil, said that quantitative coronary angiography and intravascular ultrasound of the 15 patients who had reached the 12-month timepoint revealed good coverage of their stents by endothelium, and no evidence of in-stent or edge restenosis. Moreover, there has been no evidence of adverse events with the stent, and there have been no deaths, myocardial infarctions, stent thromboses or repeat revascularizations in the patients treated to date.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze